Product Description
Bronchodilator for chronic obstructive lung disease caused by bronchial spasms of maintenance treatment, including chronic bronchitis and emphysema.With inhaled beta agonists and used in the treatment of chronic obstructive lung diseases including chronic bronchitis and asthma caused by acute bronchospasm.
AI Product Description
*The following content is generated by AI and is for reference only.
Ipratropium bromide is a quaternary ammonium anticholinergic medication widely utilized in the management of respiratory disorders. Chemically, it is synthesized as the bromide salt of ipratropium, which acts as a competitive antagonist at muscarinic acetylcholine receptors within the bronchial smooth muscle. Its molecular formula is C19H30BrNO4, and it is universally identified by the CAS Registry Number 51872-37-6. The compound possesses a complex structure featuring a tropine ring linked to a phenylcyclohexyl group, modified with an ester linkage and a quaternary nitrogen atom that prevents systemic absorption when administered via inhalation.
The primary clinical application of ipratropium bromide involves the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. By blocking the vagal nerve reflexes that cause bronchoconstriction, it effectively relaxes airway smooth muscles, thereby improving airflow and reducing symptoms such as wheezing, shortness of breath, and coughing. It is frequently prescribed as a maintenance therapy for patients requiring long-term bronchodilation. Additionally, while less common than its COPD usage, it is sometimes employed off-label or in combination therapies for acute asthma exacerbations, particularly in emergency settings where rapid relief is necessary but beta-agonists alone are insufficient.
Unlike many other bronchodilators, ipratropium bromide does not cross the blood-brain barrier significantly due to its charged nature, resulting in a favorable safety profile with minimal central nervous system side effects. Common adverse reactions are generally localized to the site of administration and may include dry mouth, bitter taste, or throat irritation. It is available in various formulations, including metered-dose inhalers, nebulizer solutions, and dry powder inhalers, allowing for flexible dosing strategies tailored to individual patient needs. Often used in conjunction with beta-2 agonists like albuterol, ipratropium bromide represents a cornerstone in modern respiratory pharmacotherapy, offering reliable symptom control and improved quality of life for millions of patients suffering from obstructive lung diseases worldwide.